Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build ...

Spread the loveYou’ve heard the buzz around cloud infrastructure, right? Specifically, Google Cloud Platform (GCP) is making ...

Spread the love“`html If you’re a developer spending any significant amount of time wrangling data, you’ve likely felt the ...

Modern data architectures require highly optimized code. A raw Python script cannot process a ten-gigabyte dataset effectively. To solve this problem engineering teams use pre-compiled Python ...

On Tuesday, Meta launched “Muse Image,” a new AI image-generation feature that allows users to create original images, edit existing photos, and even generate custom ads directly within its apps. But ...

Create a professional email identity by setting up your custom email domain. This guide walks you through every step to get your personalized email address up and running. Creating your own email ...

Mindgard used a simple “restore this image” prompt (with no image attached) to see how easily ChatGPT could be steered into unsafe territory. An adversarial testing researcher named Jim Nightingale ...

There has been a sharp rise in so-called "nudification" technology. These AI-powered tools can generate realistic fake images and videos that depict people as undressed, often without their knowledge ...

NASHVILLE, Tenn. (WSMV) - A Nashville man was arrested this week for posting numerous sexual images depicting children online over the course of several months. An arrest affidavit from the Metro ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...